1. At a Glance
When Bhagavad Gita says, “You have a right to perform your prescribed duties, but you are not entitled to the fruits of your actions,” it might as well have been directed at Lincoln Pharmaceuticals Ltd this quarter — because while the company’s sales climbed, its profits… took a nap.
Incorporated in 1979, this Ahmedabad-based pharma player (BSE: 531633 | NSE: LINCOLN) has turned itself from a small generic maker into a global exporter with 600+ formulations across 15 therapeutic areas. Its EU-GMP, TGA, and WHO-GMP certified plants in Khatraj and Mehsana are humming with activity — and solar panels, because 65% of energy comes from their own renewable sources (clearly, the only thing greener than their packaging is their power bill).
As of November 2025, the stock trades at ₹543, down about -2.6% in 3 months and -14.4% over the year, with a market cap of ₹1,087 crore. It’s almost debt-free (Debt: ₹0.07 crore), has a P/E of 13.6, ROE of 12.8%, and ROCE of 17.3% — which means it’s not flashy, but it’s stable, like a Maruti Swift that’s been through 10 Diwalis and still starts in one go.
Exports form a whopping 62.6% of revenues, while domestic contributes 37.4%. The company recently completed expansion of its Cephalosporin plant at Mehsana and has begun domestic sales — with plans to register the new products for export.
Revenue this quarter? ₹170.6 crore. Profit after tax? ₹20 crore (down 24.1% QoQ). OPM? A decent 15.8%. And dividend? ₹1.80 per share.
Basically, it’s a cautious tale of steady progress, global expansion, and one profit curve that needs a mild adrenaline shot.
2. Introduction
Let’s talk about Lincoln Pharma — a company that seems to have taken the phrase “slow and steady wins the race” a little too literally. Founded in 1979, back when bell-bottoms were in fashion and “pharma exports” meant a briefcase of tablets to Nairobi, this company now ships to over 60 countries across Europe, Africa, Canada, and Asia Pacific.
It’s the kind of midcap that quietly keeps growing without ever getting a full spotlight. The ones where investors stumble upon it while comparing peers and go, “Wait, this company makes 600 formulations?!”
Lincoln has evolved into a manufacturing-led export house with a sharp focus on generic formulations — spanning dermatology, anti-infectives, and anti-asthmatics, among others. Its global certifications (EU-GMP, TGA, WHO-GMP) have opened up the export play big time — 62.6% of revenue now comes from beyond India’s borders.
Of course, Lincoln’s story isn’t all roses and clean audits. The company’s revenue growth over the last five years stands at just 10% CAGR, which in pharma-speak is like being the quiet kid in class who always submits homework but never tops. Its profit growth is slowing too (down 17.2% YoY), but management insists on building a strong portfolio in chronic and lifestyle segments — women’s healthcare and dermatology, in particular.
Maybe it’s the calm before the next export storm. Or maybe it’s just another quarter of “steady as she goes.” Either way, Lincoln seems determined to stay relevant, profitable, and solar-powered.
3. Business Model – WTF Do They Even Do?
Alright, let’s decode Lincoln’s business model before it dissolves faster than an effervescent paracetamol.
At its core, Lincoln manufactures and trades pharmaceutical formulations — tablets, capsules, syrups, ointments, and injectables — across 15 therapeutic categories. They aren’t doing cutting-edge biotech stuff; think more “bread and butter” formulations that fill prescriptions across continents.
Therapeutic playground: From cough and cold remedies to gynaecological, anti-diabetic, dermatological, and cardiac products — if it fits in a blister pack, Lincoln’s probably making it.
Production muscle:
- Khatraj Units 1 & 2 (Gujarat): The EU-GMP, TGA, and WHO-GMP certified showpieces. Combined capacity includes 3 billion+ tablets, 2.3
